Alias: CAY10572; CAY-10572; CAY 10572; PHA767491; PHA-767491; PHA 767491
Cat No.:V0062 Purity: ≥98%
PHA-767491 (formerly also called CAY10572) is a novel and potent ATP-competitive dual inhibitor of Cdc7/CDK9 with IC50 of 10 nM and 34 nM in cell-free assays, respectively.
PHA-767491 Chemical Structure CAS No.: 845714-00-3
Product category: CDK
This product is for research use only, not for human use. We do not sell to patients.
Size Price Stock Qty
Other Sizes

Other Forms of PHA-767491:

  • PHA-767491 HCl
Official Supplier of:
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Alternate Text
Top Publications Citing lnvivochem Products
Purity & Quality Control Documentation

Purity: ≥98%

Product Description

PHA-767491 (formerly also called CAY10572) is a novel and potent ATP-competitive dual inhibitor of Cdc7/CDK9 with IC50 of 10 nM and 34 nM in cell-free assays, respectively. It exhibits approximately 20-fold selectivity against CDK1/2 and GSK3-β, 50-fold selectivity against MK2 and CDK5, and 100-fold selectivity against PLK1 and CHK2. These results suggest that it may have anticancer potential. Unlike 5-FU or gemcitabine, which only works in a few cell lines, PHA-767491 significantly induces apoptosis in a p53-independent manner in almost all cell lines. It also inhibits cell proliferation in a variety of human cell lines, with IC50 values ranging from 0.86 μM for SF-268 to 5.87 μM for K562. An important kinase called CDC7 stimulates replication origins to facilitate DNA replication. PHA-767491 inhibits the synthesis of DNA and modifies the replicative DNA helicase's phosphorylation at CDC7-dependent phosphorylation sites. PHA-767491, in contrast to existing DNA synthesis inhibitors, inhibits replication origin activation without impeding replication fork progression or causing a prolonged DNA damage response. In preclinical cancer models, PHA-767491 treatment induces apoptotic cell death in a variety of cancer cell types and inhibits tumor growth. PHA-767491 is the first known molecule to directly influence the mechanisms governing initiation rather than elongation in DNA replication, and its actions imply that inhibiting Cdc7 kinase may be a novel approach to the development of anticancer treatments.

Biological Activity I Assay Protocols (From Reference)
CDK9 (IC50 = 34 nM); CDK2 (IC50 = 240 nM); CDK1 (IC50 = 250 nM); CDK5 (IC50 = 460 nM); GSK3-β (IC50 = 220 nM); Mk2 (IC50 = 470 nM); Plk1 (IC50 = 980 nM); Chk2 (IC50 = 1100 nM)
ln Vitro
PHA-767491 has an IC50 of 0.64 µM in HCC1954 cells and 1.3 µM in Colo-205 cells, which means that it inhibits proliferation in both cell lines. PHA-767491 exhibits IC50 values of 18.6 nM, making it an effective DDK inhibitor in vitro. In HCC1954 cells, PHA-767491 (2 µM) totally eliminates Mcm2 phosphorylation within 24 hours[1]. When combined with 5-FU, PHA-767491 exhibits much greater cytotoxicity and significantly induces apoptosis, as evidenced by noticeably increased caspase 3 activation and fragmentation of poly(ADP-ribose) polymerase in HCC cells. By directly opposing the phosphorylation of Chk1 induced by 5-FU, PHA-767491 also suppresses the expression of the anti-apoptotic protein myeloid leukemia cell 1ine[2]. In a time- and dose-dependent manner, PHA-767491 (0-10 µM) reduces the viability of glioblastoma cells, with an IC50 of roughly 2.5 µM for U87-MG and U251-MG cells. In addition to inhibiting glioblastoma cell proliferation, migration, and invasion, PHA-767491 hydrochloride causes apoptosis in these cells[3].
ln Vivo
PHA-767491 promotes in situ cell apoptosis and reduces Chk1 phosphorylation in tumor tissues sectioned from naked mice HCC xenografts[2].
Enzyme Assay
For five minutes, 20 ng of purified human DDK is pre-incubated with DDK inhibitors at escalating concentrations. Next, in a buffer containing 50 mM Tris-HCl (pH 7.5), 10 mM MgCl2, and 1 mM DTT, 10 µCi (γ)-32P ATP and 1.5 µM cold ATP are added, and the mixture is incubated for 30 minutes at 30°C. The proteins are autoradiographed on HyBlot CL film and SDS-PAGEd after being denatured in 1X Laemmli buffer at 100°C. DDK's auto-phosphorylation is a measure of its kinase activity. Using ImageJ, 32P-labeled bands are quantified, and GraphPad is used to compute the IC50 values.
Cell Assay
There are 2500 cells plated in each well of 96-well plates used for assays. Cells undergo treatment with small molecule inhibitors after 24 hours, and they are then incubated at 37°C for 72 hours. Next, the cells undergo lysis, and the CellTiter-Glo assay is employed to quantify the ATP content, which serves as a marker of metabolically active cells. Utilizing GraphPad software, IC50 values are determined. 100,000 cells are plated per well in six-well plates used for assays. Small molecule inhibitors are applied to the cells after a day, and they are then cultured for different lengths of time. Trypsinized cells are suspended in 5 milliliters of phosphate-buffered saline. After mixing 30 µL of this suspension with 30 µL of CellTiter-Glo reagent, it is incubated at room temperature for 10 minutes. The EnVision 2104 Multilabel Reader and the BioTek Synergy Neo Microplate Reader are used to measure luminosity.
Animal Protocol
Dissolved in DMSO, and diluted in saline; 50 mg/kg; Intravenous or oral administration twice a day
Female SCID mice subcutaneously implanted with HL60 cells, male Hsd, athymic nu-nu mice subcutaneously implanted with HCT116 cells, A2780 or Mx-1 cells, and female Sprague-Dawley rats with DMBA-induced mammary carcinomas.

[1]. The potent Cdc7-Dbf4 (DDK) kinase inhibitor XL413 has limited activity in many cancer cell lines and discovery of potential new DDK inhibitor scaffolds. PLoS One. 2014 Nov 20;9(11):e113300.

[2]. Dual Inhibition of Cdc7 and Cdk9 by PHA-767491 Suppresses Hepatocarcinoma Synergistically with 5-Fluorouracil. Curr Cancer Drug Targets. 2015;15(3):196-204.

[3]. Cell division cycle 7-kinase inhibitor PHA-767491 hydrochloride suppresses glioblastoma growth and invasiveness. Cancer Cell Int. 2016 Nov 18;16:88.

[4]. A Cdc7 kinase inhibitor restricts initiation of DNA replication and has antitumor activity. Nat Chem Biol. 2008 Jun;4(6):357-65.

These protocols are for reference only. InvivoChem does not independently validate these methods.
Physicochemical Properties
Molecular Formula
Molecular Weight
Exact Mass
Elemental Analysis
C, 67.59; H, 5.20; N, 19.71; O, 7.50
Related CAS #
PHA-767491 hydrochloride;942425-68-5
Solid powder
InChi Key
InChi Code
Chemical Name
CAY10572; CAY-10572; CAY 10572; PHA767491; PHA-767491; PHA 767491
HS Tariff Code

Powder      -20°C    3 years

                     4°C     2 years

In solvent   -80°C    6 months

                  -20°C    1 month

Shipping Condition
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
Solubility Data
Solubility (In Vitro)
DMSO: ~24 mg/mL (~96.1 mM)
Water: <1 mg/mL
Ethanol: <1 mg/mL
Solubility (In Vivo)
1%DMSO+30% polyethylene glycol+1%Tween 80: 30mg/mL
 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 4.0048 mL 20.0240 mL 40.0481 mL
5 mM 0.8010 mL 4.0048 mL 8.0096 mL
10 mM 0.4005 mL 2.0024 mL 4.0048 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.


Molarity Calculator allows you to calculate the mass, volume, and/or concentration required for a solution, as detailed below:

  • Calculate the Mass of a compound required to prepare a solution of known volume and concentration
  • Calculate the Volume of solution required to dissolve a compound of known mass to a desired concentration
  • Calculate the Concentration of a solution resulting from a known mass of compound in a specific volume
An example of molarity calculation using the molarity calculator is shown below:
What is the mass of compound required to make a 10 mM stock solution in 5 ml of DMSO given that the molecular weight of the compound is 350.26 g/mol?
  • Enter 350.26 in the Molecular Weight (MW) box
  • Enter 10 in the Concentration box and choose the correct unit (mM)
  • Enter 5 in the Volume box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 17.513 mg appears in the Mass box. In a similar way, you may calculate the volume and concentration.

Dilution Calculator allows you to calculate how to dilute a stock solution of known concentrations. For example, you may Enter C1, C2 & V2 to calculate V1, as detailed below:

What volume of a given 10 mM stock solution is required to make 25 ml of a 25 μM solution?
Using the equation C1V1 = C2V2, where C1=10 mM, C2=25 μM, V2=25 ml and V1 is the unknown:
  • Enter 10 into the Concentration (Start) box and choose the correct unit (mM)
  • Enter 25 into the Concentration (End) box and select the correct unit (mM)
  • Enter 25 into the Volume (End) box and choose the correct unit (mL)
  • Click the “Calculate” button
  • The answer of 62.5 μL (0.1 ml) appears in the Volume (Start) box

Molecular Weight Calculator allows you to calculate the molar mass and elemental composition of a compound, as detailed below:

Note: Chemical formula is case sensitive: C12H18N3O4  c12h18n3o4
Instructions to calculate molar mass (molecular weight) of a chemical compound:
  • To calculate molar mass of a chemical compound, please enter the chemical/molecular formula and click the “Calculate’ button.
Definitions of molecular mass, molecular weight, molar mass and molar weight:
  • Molecular mass (or molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
  • Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Reconstitution Calculator allows you to calculate the volume of solvent required to reconstitute your vial.

  • Enter the mass of the reagent and the desired reconstitution concentration as well as the correct units
  • Click the “Calculate” button
  • The answer appears in the Volume (to add to vial) box
In vivo Formulation Calculator (Clear solution)
Step 1: Enter information below (Recommended: An additional animal to make allowance for loss during the experiment)
Step 2: Enter in vivo formulation (This is only a calculator, not the exact formulation for a specific product. Please contact us first if there is no in vivo formulation in the solubility section.)

Calculation results

Working concentration mg/mL;

Method for preparing DMSO stock solution mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.

Method for preparing in vivo formulation:Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.

(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
             (2) Be sure to add the solvent(s) in order.

Biological Data
  • PHA-767491

    CDC7 inhibition suppresses glioblastoma cell invasion2016 Nov 18;16:88.
  • PHA-767491

    CDC7 inhibition induces apoptosis in glioblastoma cells2016 Nov 18;16:88.

  • PHA-767491

    CDC7 inhibition decreases glioblastoma cell viability in a time- and dose-dependent
Contact Us Back to top